EUCTR2011-001841-34-GB进行中（未招募）1 期
A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium. - PLUTO (PAZOPANIB VERSUS PACLITAXEL IN RELAPSED UROTHELIAL TUMOURS)
HS Greater Glasgow Health Board0 个研究点目标入组 131 人开始时间: 2011年11月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 131
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Histologically or cytologically confirmed TCC (bladder, renal pelvis, ureter, urethra), which is locally advanced or metastatic (T4b and/or N1-3 and/or M1). Patients with mixed or differentiation pattern pathology will be permitted entry providing that TCC is a component pathology. 2.Progressive disease during or after one prior platinum-based chemotherapy regimen for advanced disease or as peri-operative therapy for muscle-invasive / node positive disease (if completed < 12 months prior to documented disease progression). The regimen must have included either cisplatin or carboplatin. Patients who have had two platinum containing regimens are eligible if one of these was given peri-operatively, and provided that there was a chemotherapy-free interval of at least 12 months between completing the 1st course and commencing the second course of chemotherapy. Chemotherapy given during radical radiotherapy as a radiosensitizer will not be considered as a chemotherapy treatment for the purposes of study eligibility. 3.Age = 18 years. 4.Measurable disease by RECIST 1.1. 5.Adequate organ function as defined by the following criteria: •Total serum bilirubin =1.5 x upper level of normal (ULN). •Serum transaminases <2.5 x ULN. Concomitant elevations of transaminases and bilirubin are not permitted. •Creatinine clearance >30ml/min (calculated by Cockcroft Gault equation) or Creatinine =1.5 x ULN. •Absolute neutrophil count (ANC) =1500/mm3 without growth factor support •Platelets = 100,000/mm3 •Urine protein to creatinine ratio (UPC) < 110 mg/mmol (1g/g) (or total urinary protein < 1g/24hrs) •Activated partial thromboplastin time (APTT) =1.2 x ULN •International normalised ratio (INR)= 1.2 6.Signed and dated informed consent indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment. 7.A negative pregnancy test for women of childbearing potential. 8.Life expectancy of 3 months or more. 9.Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures. 10.ECOG performance status of 0 or 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 42
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 98
排除标准
- •1.Congestive heart failure, myocardial infarction, coronary artery bypass graft or thrombotic cerebrovascular event in the previous six months, or ongoing severe or unstable arrhythmia requiring medication. Patients with rate controlled atrial fibrillation are permitted to enter the study. 2.History of clinically significant bleeding in the 6 months prior to study initiation (including haemoptysis, cerebrovascular bleed or haematemesis; patients with haematuria are permitted entry as long as there is no indication for intervention). 3.Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any unhealed wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery). 4.Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been therapeutically anti-coagulated for at least 6 weeks are eligible. 5.History of another malignancy in the last 5 years (other than treated squamous/basal cell skin cancer, treated early stage cervical cancer or treated / biochemically stable, organ confined prostate cancer). 6.Ongoing major gastrointestinal disease including unstable inflammatory bowel disease or bleeding peptic ulcer disease. 7.Known endobronchial lesions which have a high risk of pulmonary haemorrhage . 8.Previously identified brain, or central nervous system (CNS) metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants in prior 28 days. 9.Pregnant or breastfeeding. Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. Male patients must be surgically sterile or agree to use effective contraception. 10.Administration of any investigational drug within 28 days or 5 half lives, whichever is longer, prior to receiving the first dose of study treatment 11.Treatment with any of the following anti-cancer therapies: Radiation therapy, surgery or tumour embolisation within 14 days prior to the first dose of study medication Chemotherapy, immunotherapy, biologic therapy, investigational therapy within 28 days or 5 half-lives of a drug (whichever is longer) prior to the first dose of study medication. 12.Peripheral neuropathy of grade 2 or more. 13.Any on-going toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity, except alopecia. 14.Other severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or lab finding that makes it undesirable for the patient to participate in the study. 15.Any psychological, familial, sociological or geographical consideration potentially hampering compliance with the study protocol and follow up schedule; those considerations should be discussed with the patient before registration in the trial. 16.Known HIV or other chronic immunosuppressive disease. 17. QTc that is immeasurable or >480 msec on screening ECG. (Note: If a subject has a QTc interval >480 msec on screening ECG, the screening ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be <
研究者
相似试验
进行中（未招募）
不适用
A 12-Week Study of Eye Drops to Treat Wet Age-related Macular Degeneration (AMD)Age-related macular degeneration (AMD)MedDRA version: 14.0Level: PTClassification code 10025409Term: Macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2011-000243-24-DEGlaxoSmithKline Research & Development Ltd.30
已完成
2 期
Pazopanib versus pacLitaxel in relapsed Urothelial TumOursCancerISRCTN73030316HS Greater Glasgow and Clyde (UK)131
进行中（未招募）
1 期
A randomized multicentre phase II trial with pazopanib and weekly paclitaxel vs weekly paclitaxel in platinum resistant or refractory ovarian cancer - MITO - 11platinum resistant or refractory ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033130EUCTR2009-016151-21-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE72
进行中（未招募）
1 期
Comparison of pazopanib with doxorubicin as first medication for elderly patients with severe soft tissue sarcomaEUCTR2011-004168-30-BEHannover Medical School120
进行中（未招募）
1 期
Comparison of pazopanib with doxorubicin as first medication for elderly patients with severe soft tissue sarcomaMetastatic or advanced soft tissue sarcomaMedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004168-30-DEHannover Medical School